Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase

References

• Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian H. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164–172
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shan J, Smith T, Talpaz M, Kozuch P, Rios M, et al. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blast phase. Cancer 2001; 92: 2501–2507
   PubMed Web of Science ®Google Scholar
• Wadhwa J, Szydlo R, Apperley J, Chase A, Bua M, Marin D, et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 2002; 99: 2304–2309
   PubMed Web of Science ®Google Scholar
• O'Dwyer M, Mauro M, Druker B. Recent advancements in the treatment of chronic myelogenous leukemia. Ann Rev Med 2002; 53: 369–381
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrman M, Hehlmann R, Allan N, Baccarani M, Kluin-Nelemans J, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998; 90: 850–858
   PubMed Web of Science ®Google Scholar
• Sokal J, Cox E, Baccarani M, Tura S, Gomez G, Robertson J, et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 1984; 63: 789–799
   PubMed Web of Science ®Google Scholar
• Braga G, Chauffaille M, Cajado Moncau J, Xisto Souto E, Regis Silva M, Kerbauy J. Chronic myeloid leukemia (CML): prognostic factors and survival analysis. São Paulo Med J 1996; 114: 1083–1090
   PubMedGoogle Scholar
• Goldman J, Druker B. Chronic myeloid leukemia: current treatment options. Blood 2001; 98: 2039–2042
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Smith T, O'Brien S, Beran M, Pierce S, Talpaz M, Leukemia Service. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995; 122: 254–261
   PubMed Web of Science ®Google Scholar
• Steegman J, Odriozola J, Rodriguez-Salvanes F, Giraldo P, Garcia-Larana J, Ferro M, et al. Stage, percentage of basophils at diagnosis, hematologic response with-in six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-α. Results of the CML89 trial of the Spanish Collaborative Group on interferon-α2a and CML. Haematologica 1999; 84: 978–987
   PubMed Web of Science ®Google Scholar
• Bonifazi F, de Vivo A, Rosti G, Guilhot F, Trabacchi E, Hehlmann R, et al. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders. Blood 2001; 98: 3074–3081
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Hochhaus A, Berger U, Reiter A. Current trends in the management of chronic myelogenous leukemia. Ann Hematol 2000; 79: 345–354
   PubMed Web of Science ®Google Scholar
• Silver R, Woolf S, Hehlmann R, Appelbaum F, Anderson J, Bennett C, et al. An evidence based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999; 94: 1517–1536
   PubMed Web of Science ®Google Scholar
• Druker B. Imatinib alone and in combination for chronic myeloid leukemia. Seminars in Hematology 2003; 40: 50–58
   PubMed Web of Science ®Google Scholar
• O'Brien S, Guilhot F, Larson R A, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004, [abstract]
   PubMed Web of Science ®Google Scholar
• , et al. UnGraph for Windows. 4.0. Biosoft, CambridgeUK 1998
   Google Scholar
• , et al. The GLIM System. 4.0. Oxford University Press, OxfordUK 1993
   Google Scholar
• , et al. S-Plus 2000 user's guide. Data Analysis Products Division, Mathsoft, Seattle, WA 1999
   Google Scholar
• Benelux CML Study Group. Randomised study on hydroxyurea alone versus hydroxyurea combined with low dose interferon-α2b for chronic myeloid leukaemia. Blood 1998; 91: 2713–2721
   PubMedGoogle Scholar
• Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau J, Maloisel F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997; 337: 223–229
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Heimpel H, Hasford J, Kolb H, Pralle H, Hossfeld D, et al. Randomised comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064–4077
   PubMed Web of Science ®Google Scholar
• Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long term follow up of the Italian Trial of interferon-alfa versus conventional chemotherapy in chronic myeloid leukaemia. Blood 1998; 92: 1541–1548
   PubMed Web of Science ®Google Scholar
• Ohnishi K, Ohno R, Tomonaga M, Kamada M, Onozawa K. A randomised trial comparing interferon-alfa with busulfan for newly diagnosed chronic myeloid leukemia in chronic phase. Blood 1995; 86: 906–916
   PubMed Web of Science ®Google Scholar
• Allan N, Richards S, Shepherd P. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392–1397
   PubMed Web of Science ®Google Scholar
• Baccarani M, Rosti G, de Vivo A, Bonifazi F, Russo D, Martinelli G, et al. A randomised study of interferon-α versus interferon-α and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002; 99: 1527–1535
   PubMed Web of Science ®Google Scholar
• Johnson J, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003; 21: 1404–1411
   PubMed Web of Science ®Google Scholar
• Koopmans P. Clinical endpoints in trials of drugs for cancer: time for a rethink. Br Med J 2002; 324: 1389–1391
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrman M, Hehlmann R, Baccarani M, Guilhot F, Mahon F, et al. Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy. Semin Hematol 2003; 40: 4–12
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Ansari H, Hasford J, Heimpel H, German CML Group. Chronic myelogenous leukemia: Progress in chemotherapy and evaluation of prognostic score 1. Semin Hematol 1993; 30: 44–48
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 2002; 82: 691–703
   Google Scholar
• Hasford J, Pfirrman M, Shepherd P, Guilhot J, Hehlmann R, Mahon F, et al. The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon-α. Haematologica 2005; 90: 335–340
   PubMed Web of Science ®Google Scholar
• Cervantes F, Hernandez-Boluda J, Steegman J, Conde E, Alvarez-Larran A, Lopez-Jimenez J, et al. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. Haematologica 2003; 88: 1117–1122
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, et al. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-α regimens for early chronic phase. Cancer 2003; 98: 1430–1437
   PubMed Web of Science ®Google Scholar